This course has expired. View available courses.
Oncology, Women's Health
Managing Pre-Menopausal Patients with HR-HER2 Breast Cancer
Advanced breast cancer in pre-menopausal women is often more aggressive when compared to breast cancer in older women. Treatment strategies for younger women are usually extrapolated from data pertaining to post-menopausal patients, with the addition of ovarian function suppression in hormone receptor positive (HR+) disease. This 30-minute program, endorsed by the Clinical Oncology Society of […]
DURATION
0.5 hrs
PROFESSION
Specialist
# OF CREDITS
0.5
ACCREDITATION
Certificate of Completion
EXPIRY DATE
2021-01-13
Advanced breast cancer in pre-menopausal women is often more aggressive when compared to breast cancer in older women. Treatment strategies for younger women are usually extrapolated from data pertaining to post-menopausal patients, with the addition of ovarian function suppression in hormone receptor positive (HR+) disease.
This 30-minute program, endorsed by the Clinical Oncology Society of Australia (COSA), features a summary of HR-positive, HER2-negative metastatic breast cancer, highlights from the MONALESSA-7 trial, including key efficacy and safety data in support of endocrine therapy plus ribociclib as first-line treatment for pre-menopausal women with HR+/HER2- advanced breast cancer.
With a comprehensive case study that focusses on the importance of treatment, management and monitoring of endocrine therapy plus ribociclib, this program also offers expert video commentary from Dr Richard de Boer to help you optimise your practice.
Faculty
Dr Richard de Boer
MBBS, FRACP
A/Prof Elgene Lim
MBBS, PhD, FRACP
Learning objectives
Upon completion of this program, participants will be able to:
- Describe the cyclin-dependent protein kinase (CDK) 4/6 signalling pathway and its inhibitors
- Evaluate the efficacy and safety of novel targeted therapy used in the treatment of pre-menopausal women with hormone receptor-positive (HR+) breast cancer
- Identify appropriate first-line targeted therapy options for pre-menopausal women with HR+/HER2- breast cancer
- Summarise approved dosing, tolerability and monitoring of ribociclib
Accreditation
This interactive online learning activity is valued at 0.5 Hour(s) of continuing education. # of credits: 0.5
Duration: 0.5 hrs
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
